A Study of Safety Tolerability and Clinical Activity of MEDI4736 and Tremelimumab Administered as Monotherapy and in Combination to Subjects with Unresectable Hepatocellular Carcinoma
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
Conditions: hepatocellular carcinoma | liver cancer
Age: Between 18 - 100 Years
Gender: Male or Female
In order to be eligible to take part in this trial, patients must meet the following criteria:
- 18 years or older
- Confirmed diagnosis of unresectable hepatocellular carcinoma with or without concomitant viral hepatits B or hepatitis C infection
For a full list of participation criteria, please visit clinicaltrials.gov.
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required